Trajentin Duo Tablet 2.5/850 mg
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Dae Hwa Pharmaceutical Co., Ltd.
MFDS item code 201907008 · Approved 2019.10.01
This product's status changed to Expired on 2024.10.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve blood sugar control in patients with Type 2 diabetes who are using both Linagliptin and Metformin.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no previous experience with antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, the initial dose is one tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to one tablet of this medicine 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant treatment with linagliptin and metformin: Patients switching from concomitant treatment with linagliptin and metformin to this medicine should start with their existing doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with concomitant metformin and sulfonylurea: The initial dose should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see section 2, Patients Requiring Cautious Administration, under Precautions for Use). 5. Patients unable to achieve adequate glycemic control with concomitant insulin and metformin: The initial dose should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see section 2, Patients Requiring Cautious Administration, under Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. As the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 1, Patients Who Must Not Take This Medicine, under Precautions for Use).
This medication can cause a serious complication called lactic acidosis, and should not be administered to patients with impaired kidney function or liver function issues. Patients with allergies to any components of this medication, Type 1 diabetes, acute cardiac disease, or those with severe infections should also not use this medication. Pregnant or nursing women are advised not to take this medication, and those who are planning to become pregnant should consult a physician. Since this medication has a blood sugar-lowering effect, caution must be taken for symptoms of hypoglycemia when used in combination with other blood sugar-lowering agents, and dosages of other medications may need to be adjusted as necessary. Regular blood tests should be carried out to monitor kidney status in situations where there is a risk of kidney function decline, and the medication should be discontinued immediately if acute kidney impairment is suspected. If iodine contrast agents used in radiological examinations are administered, it is necessary to discontinue the medication for a certain period before and after the examination and to re-evaluate kidney function. During the use of this medication, symptoms such as gastrointestinal disorders, abdominal pain, and muscle weakness may occur, and a physician should be informed if these symptoms persist or worsen. Furthermore, this medication may lower vitamin B12 levels, so it is necessary to check vitamin B12 status through blood tests if used for long periods. If symptoms of rare skin or pancreatic conditions such as blistering dermatitis or acute pancreatitis occur, the medication should be stopped immediately, and medical consultation should follow. Elderly patients are at higher risk of decreased kidney function, so it is important to adjust the dosage of this medication and frequently check kidney function. While there is insufficient research regarding the effects on driving or machine operation, caution is needed as hypoglycemic symptoms may occur. Overdosage may lead to dangerous situations like lactic acidosis, so it is essential to adhere strictly to the prescribed dosage and visit a hospital immediately if there are any unusual symptoms. This medication should be stored in a tightly closed container away from moisture and out of reach of children, and it is advisable not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture. The recommended storage temperature is between 1 to 30 degrees Celsius at room temperature. This helps to maintain the medication's efficacy and prevent degradation.
Bright orange, biconvex oval film-coated tablet
30 tablets/box [6 tablets/PTP x 5]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Dae Hwa Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.